异烟肼血药浓度的影响因素分析
|
摘要
目的:分析影响异烟肼血药浓度的因素。方法:对2013年9月～2017年12月的97例异烟肼血药浓度监测患者作回顾性分析,探讨影响异烟肼血药浓度的主要因素。结果:该药血药浓度与体表面积和白蛋白水平存在显著相关性。结论:密切关注具有危险因素患者的血药浓度。
Objective:To analyze the influencing factors on plasma concentrations of isoniazid.Method:A retrospective analysis was performed on 97 patients who were monitored for plasma concentrations of isoniazid from September 2013 to December 2017.Result:Body surface area and albumin level were significant factors correlated with plasma concentrations of isoniazid.Conclusion:Patients with risk factors should pay close attention to the plasma concentration of isoniazid.
Objective:To analyze the influencing factors on plasma concentrations of isoniazid.Method:A retrospective analysis was performed on 97 patients who were monitored for plasma concentrations of isoniazid from September 2013 to December 2017.Result:Body surface area and albumin level were significant factors correlated with plasma concentrations of isoniazid.Conclusion:Patients with risk factors should pay close attention to the plasma concentration of isoniazid.
引文
[1]郎美琦,蒋利,黄佳盛.抗结核病药物治疗综述[J].临床肺科杂志,2010,15(8):1153-4.
[2]Jung JA,Kim TE,Lee H,et al.Aproposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis[J].Drug Des Deve Ther,2015,15(9):5433-8.
[3]Luangchosiri C,Thakkinstian A,Chitphuk S,et al.Adouble-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury[J].BMC Complement Altern Med,2015,15(1):334.
[4]张亮,钱智磊,陆磊,等.同时测定血浆INH、AcINH、RFP和PZA的高效液相色谱法建立及其在肺结核患者中的应用[J].山东医药,2015,55(48):23-6.
[5]Golka K,Selinski S.NAT2 Genotype and Isoniazid Medication in Children[J].E Bio Medicine,2016,11(8):11-2.
[6]Azuma J,Ohno M,Kubota R,et al.NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis:a randomized controlled trial for pharmacogenetics-based therapy[J].Eur J Clin Pharmacol,2013,69(5):1091-101.
[7]张亮,钱智磊,陆磊,等.高效液相色谱法同时测定人血浆中异烟肼、乙酰异烟肼和吡嗪酰胺的浓度[J].药学与临床研究,2014,22(2):112-4.
[8]钱智磊,陆磊,周秋云,等.HPLC法测定结核病患者血浆中异烟肼、吡嗪酰胺和利福平的质量浓度[J].西北药学杂志,2013,28(6):611-4.
[9]曹津津,周秋云,钱智磊,等.利用基因检测技术指导氯吡格雷的合理应用[J].药学与临床研究,2017,25(3):251-2.
[10]Um SW,Lee SW,Kwon SY,et al.Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels[J].Int J Tuberc Lung Dis,2007,11(9):972-8.
[11]Park JS,Lee JY,Lee YJ.Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome[J].Antimicrob Agents Chemother,2015,60(1):92-8.
[12]J onsson S,Davidse A,Wilkins J,et al.Population pharmacokinetics of ethambutol in South African tuberculosis patients[J].Antimicrob Agents Chemother,2011,55(9):4230-7.
[13]Du H,Chen X,Fang Y,et al.Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity:a meta-analysis[J].Mol Biol Rep,2013,40(5):3591-6.
[14]Chamorro JG,Castagnino JP,Musella RM,et al.The distribution of allelic and genotypic frequencies of,N-Acetyltransferase-2 variants in an Argentine population[J].J Infect Dev Ctries,2012,56(9):671-4.
[15]Hein DW,Doll MA.Accuracy of various human NAT2SNP genotyping panels to infer rapid,intermediate and slow acetylator phenotypes[J].Pharmacogenomics,2012,13(1):31-41.
[2]Jung JA,Kim TE,Lee H,et al.Aproposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis[J].Drug Des Deve Ther,2015,15(9):5433-8.
[3]Luangchosiri C,Thakkinstian A,Chitphuk S,et al.Adouble-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury[J].BMC Complement Altern Med,2015,15(1):334.
[4]张亮,钱智磊,陆磊,等.同时测定血浆INH、AcINH、RFP和PZA的高效液相色谱法建立及其在肺结核患者中的应用[J].山东医药,2015,55(48):23-6.
[5]Golka K,Selinski S.NAT2 Genotype and Isoniazid Medication in Children[J].E Bio Medicine,2016,11(8):11-2.
[6]Azuma J,Ohno M,Kubota R,et al.NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis:a randomized controlled trial for pharmacogenetics-based therapy[J].Eur J Clin Pharmacol,2013,69(5):1091-101.
[7]张亮,钱智磊,陆磊,等.高效液相色谱法同时测定人血浆中异烟肼、乙酰异烟肼和吡嗪酰胺的浓度[J].药学与临床研究,2014,22(2):112-4.
[8]钱智磊,陆磊,周秋云,等.HPLC法测定结核病患者血浆中异烟肼、吡嗪酰胺和利福平的质量浓度[J].西北药学杂志,2013,28(6):611-4.
[9]曹津津,周秋云,钱智磊,等.利用基因检测技术指导氯吡格雷的合理应用[J].药学与临床研究,2017,25(3):251-2.
[10]Um SW,Lee SW,Kwon SY,et al.Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels[J].Int J Tuberc Lung Dis,2007,11(9):972-8.
[11]Park JS,Lee JY,Lee YJ.Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome[J].Antimicrob Agents Chemother,2015,60(1):92-8.
[12]J onsson S,Davidse A,Wilkins J,et al.Population pharmacokinetics of ethambutol in South African tuberculosis patients[J].Antimicrob Agents Chemother,2011,55(9):4230-7.
[13]Du H,Chen X,Fang Y,et al.Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity:a meta-analysis[J].Mol Biol Rep,2013,40(5):3591-6.
[14]Chamorro JG,Castagnino JP,Musella RM,et al.The distribution of allelic and genotypic frequencies of,N-Acetyltransferase-2 variants in an Argentine population[J].J Infect Dev Ctries,2012,56(9):671-4.
[15]Hein DW,Doll MA.Accuracy of various human NAT2SNP genotyping panels to infer rapid,intermediate and slow acetylator phenotypes[J].Pharmacogenomics,2012,13(1):31-41.